ArticleStem cells (Dayton, Ohio)2011
Discovery of nonsteroidal anti-inflammatory drug and anticancer drug enhancing reprogramming and induced pluripotent stem cell generation.
Article in Stem cells (Dayton, Ohio), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- A new role of iridium(III) complexes in regulating pluripotency acquisition via mitochondrial remodulation.Science China. Life sciences · 2026Article
- Inactivation of Tumor Suppressor CYLD Inhibits Fibroblast Reprogramming to Pluripotency.Cancers · 2023Article
- DOT1L inhibition enhances pluripotency beyond acquisition of epithelial identity and without immediate suppression of the somatic transcriptome.Stem cell reports · 2022Article
- An Insight into Reprogramming Barriers to iPSC Generation.Stem cell reviews and reports · 2020Review
- Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming.The Journal of biological chemistry · 2019Article
- Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.Nature chemical biology · 2019Article
- KDM6A and KDM6B play contrasting roles in nuclear transfer embryos revealed by MERVL reporter system.EMBO reports · 2018Article
- FACT Sets a Barrier for Cell Fate Reprogramming in Caenorhabditis elegans and Human Cells.Developmental cell · 2018Article
- Epigenetic Contribution of High-Mobility Group A Proteins to Stem Cell Properties.International journal of cell biology · 2018Review
- 3,3'-Diindolylmethane stimulates exosomal Wnt11 autocrine signaling in human umbilical cord mesenchymal stem cells to enhance wound healing.Theranostics · 2017Article
- Loss of PRRX1 induces epithelial-mesenchymal transition and cancer stem cell-like properties in A549 cells.American journal of translational research · 2017Article
- Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer.Frontiers in cell and developmental biology · 2017Article
- Forkhead transcription factors: new considerations for alzheimer's disease and dementia.Journal of translational science · 2016Article
- An integrated systems biology approach identifies positive cofactor 4 as a factor that increases reprogramming efficiency.Nucleic acids research · 2016Article
- Stem cell guidance through the mechanistic target of rapamycin.World journal of stem cells · 2015Review
- Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease.Neural regeneration research · 2015Review
- FoxO proteins in the nervous system.Analytical cellular pathology (Amsterdam) · 2015Review
- Programming apoptosis and autophagy with novel approaches for diabetes mellitus.Current neurovascular research · 2015Review
- New Insights for Oxidative Stress and Diabetes Mellitus.Oxidative medicine and cellular longevity · 2015Review
- MicroRNA-mediated regulation of extracellular matrix formation modulates somatic cell reprogramming.RNA (New York, N.Y.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recent breakthroughs in creating induced pluripotent stem cells (iPSCs) provide alternative means to obtain embryonic stem-like cells without destroying embryos by introducing four reprogramming factors (Oct3/4, Sox2, and Klf4/c-Myc or Nanog/Lin28) into somatic cells. iPSCs are versatile tools for investigating early developmental processes and could become sources of tissues or cells for regenerative therapies. Here, for the first time, we describe a strategy to analyze genomics datasets of mouse embryonic fibroblasts (MEFs) and embryonic stem cells to identify genes constituting barriers to iPSC reprogramming. We further show that computational chemical biology combined with genomics analysis can be used to identify small molecules regulating reprogramming. Specific downregulation by small interfering RNAs (siRNAs) of several key MEF-specific genes encoding proteins with catalytic or regulatory functions, including WISP1, PRRX1, HMGA2, NFIX, PRKG2, COX2, and TGFβ3, greatly increased reprogramming efficiency. Based on this rationale, we screened only 17 small molecules in reprogramming assays and discovered that the nonsteroidal anti-inflammatory drug Nabumetone and the anticancer drug 4-hydroxytamoxifen can generate iPSCs without Sox2. Nabumetone could also produce iPSCs in the absence of c-Myc or Sox2 without compromising self-renewal and pluripotency of derived iPSCs. In summary, we report a new concept of combining genomics and computational chemical biology to identify new drugs useful for iPSC generation. This hypothesis-driven approach provides an alternative to shot-gun screening and accelerates understanding of molecular mechanisms underlying iPSC induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.